Impact of epithelial ovarian cancer screening on patient-relevant outcomes in average-risk postmenopausal women

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 7, 2014, Pages

  Mosch, Christoph G ^a   Jaschinski, Thomas ^a   Eikermann, Michaela ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4;

ALL CAUSE MORTALITY; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; HUMAN; OVARY CARCINOMA; POPULATION RISK; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TRANSVAGINAL ECHOGRAPHY; TREATMENT OUTCOME;

EID: 85041652064     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011210     Document Type: Article

References (56)

1. Adriaensen WJ, Mathei C, Buntinx FJ, Arbyn M. A framework provided an outline toward the proper evaluation of potential screening strategies. Journal of Clinical Epidemiology 2013;66(6):639-47. [PUBMED: 23395357]
2. Aletti GD, Gallenberg MM, Cliby WA, Jatoi A, Hartmann LC. Current management strategies for ovarian cancer. Mayo Clinic Proceedings 2007;82(6):751-70. [PUBMED: 17550756]
3. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al.Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. Journal of the National Cancer Institute 2012;104(2):125-32. [PUBMED: 22228146]
4. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al.Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. American Journal of Human Genetics 2003;72(5):1117-30. [PUBMED: 12677558]
5. Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, et al.Ten-year relative survival for epithelial ovarian cancer. Obstetrics and Gynecology 2012;120(3):612-8. [PUBMED: 22914471]
6. Bankhead CR, Kehoe ST, Austoker J. Symptoms associated with diagnosis of ovarian cancer: a systematic review. British Journal of Obstetrics and Gynaecology 2005;112(7):857-65. [PUBMED: 15957984]
7. Bast, RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al.A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. New England Journal of Medicine 1983;309(15):883-7. [PUBMED: 6310399]
8. Bell R, Petticrew M, Luengo S, Sheldon TA. Screening for ovarian cancer: a systematic review. Health Technology Assessment 1998;2(2):i-iv, 1-84. [PUBMED: 9561894]
9. Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, et al.Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology 2006;102(3):432-9. [PUBMED: 16860852]
10. Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, et al.Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncology 2007;8(9):773-83. [PUBMED: 17714991]
11. Cancer Research UK. Ovarian cancer. http://www.cancerresearchuk.org/cancer-info/cancerstats/survival/common-cancers/ (accessed 3 May 2014).
12. Carlson KJ, Skates SJ, Singer DE. Screening for ovarian cancer. Annals of Internal Medicine 1994;121(2):124-32. [PUBMED: 8017726]
13. Cho KR, Shih IeM. Ovarian cancer. Annual Review of Pathology 2009;4:287-313. [PUBMED: 18842102]
14. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith GD, Altman DG editor(s). Systematic Reviews in Health Care. Second Edition. London: BMJ Publishing Group, 2001:285-312. [DOI: 10.1002/9780470693926]
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88. [PUBMED: 3802833]
16. German Cancer Society (DKG)/AWMF/German Cancer Aid. Clinical practice guideline diagnostic, therapy and after-care of malignant ovarian tumours [S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren]. www.krebsgesellschaft.de/download/s3-ovarialkarzinom-ol-langversion.pdf 2013 (accessed 3 January 2013).
17. European Parliament and the Council of the European Union. Regulation (EC) No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_141/reg_2000_141_en.pdf (accessed 10 May 2014).
18. EUCAN - International Agency for Research on Cancer (WHO). Ovarian cancer. http://eco.iarc.fr/eucan/CancerOne.aspx?Cancer=27&Gender=2#block-chart-f. EUCAN - International Agency for Research on Cancer (WHO), 2013 (accessed 7 March 2013).
19. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al.Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European Journal of Cancer 2013;49(6):1374-403. [PUBMED: 23485231]
20. Ford D, Easton DF Stratton M, Narod S, Goldgar D, Devilee P, et al.Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. American Journal of Human Genetics 1998;62(3):676-89. [PUBMED: 9497246]
21. Gates TJ. Concepts and controversies in cancer screening. American Journal of Cancer 2003;2(6):395-402. [EMBASE: 2004053940]
22. Gentry-Maharaj A, Menon U. Screening for ovarian cancer in the general population. Best Practice and Research in Clinical Obstetrics and Gynaecology 2012;26(2):243-56. [PUBMED: 22182415]
23. Goff B. Symptoms associated with ovarian cancer. Clinical Obstetrics and Gynecology 2012;55(1):36-42. [PUBMED: 22343227]
24. Higgins RV, van Nagell JR, Donaldson ES, Gallion HH, Pavlik EJ, Endicott B, et al.Transvaginal sonography as a screening method for ovarian cancer. Gynecologic Oncology 1989;34(3):402-6. [PUBMED: 2670695]
25. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
26. Hippisley-Cox J, Coupland C. Identifying women with suspected ovarian cancer in primary care: derivation and validation of algorithm. BMJ 2012;344:d8009. [PUBMED: 22217630]
27. Hong MK, Chu TY, Ding DC. The fallopian tube is the culprit and an accomplice in type II ovarian cancer: a review. Tzu Chi Medical Journal 2013;25(4):203-5. [DOI: dx.doi.org/10.1016/j.tcmj.2013.04.002]
28. Hulka BS. Cancer screening. Degrees of proof and practical application. Cancer 1988;62(8 Suppl):1776-80. [PUBMED: 3048638]
29. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Molecular and Cellular Proteomics 2004;3(4):355-66. [PUBMED: 14764655]
30. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA: Cancer Journal for Clinicians 2011;61(3):183-203. [PUBMED: 21521830]
31. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA: Cancer Journal for Clinicians 2009;59(4):225-49. [PUBMED: 19474385]
32. King MC, Marks JH, Mandell JB, New YBCSG. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302(5645):643-6. [PUBMED: 14576434]
33. Kurman RJ, Shih IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. International Journal of Gynecological Pathology 2008;27(2):151-60. [PUBMED: 18317228]
34. Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih IeM. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. American Journal of Obstetrics and Gynecology 2008;1998(4):351-6. [PUBMED: 18395030]
35. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. American Journal of Surgical Pathology 2010;34(3):433-43. [PUBMED: 20154587]
36. Kyrgiou M, Tsoumpou I, Martin-Hirsch P, Arbyn M, Prendiville W, Koliopoulos G, et al.Ovarian cancer screening. Anticancer Research 2006;26(6C):4793-801. [PUBMED: 17214343]
37. Manegold-Brauer G, Bellin AK, Tercanli S, Lapaire O, Heinzelmann-Schwarz V. The special role of ultrasound for screening, staging and surveillance of malignant ovarian tumors: distinction from other methods of diagnostic imaging. Archives of Gynecology and Obstetrics 2013 Nov 20 [Epub ahead of print]. [PUBMED: 24253338]
38. Maringe C, Walters S, Butler J, Coleman MP, Hacker N, Hanna L, et al.Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership. Gynecologic Oncology 2012;127(1):75-82. [PUBMED: 22750127]
39. Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2009;142(2):99-105. [PUBMED: 18995946]
40. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al.Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncology 2009;10(4):327-40. [PUBMED: 19282241]
41. Morrison J, Haldar K, Kehoe S, Lawrie TA. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews 2012, Issue 8. [DOI: 10.1002/14651858.CD005343.pub3; PUBMED: 22895947]
42. Moyer VA, U. S. Preventive Services Task Force (USPSTF). Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Annals of Internal Medicine 2012;157(12):900-4. [PUBMED: 22964825]
43. Nelson HD, Westhoff C, Piepert J, Berg A. Screening for Ovarian Cancer: Brief Evidence Update. AHRQ Pub. 2004; Vol. No. 04-0542-B. [: www.uspreventiveservicestaskforce.org/3rduspstf/ovariancan/ovcanup.pdf]
44. National Institute for Health and Care Excellence - NICE. Ovarian cancer: the recognition and initial management of ovarian cancer (clinical practice guideline) [CG122]. http://guidance.nice.org.uk/CG122/Guidance/pdf/English 2011.
45. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34. [PUBMED: 9921604]
46. Pavlik EJ, DePriest PD, Gallion HH, Ueland FR, Reedy MB, Kryscio RJ, et al.Ovarian volume related to age. Gynecologic Oncology 2000;77(3):410-2. [PUBMED: 10831351]
47. Pavlik EJ, van Nagell JR. Early detection of ovarian tumors using ultrasound. Women's Health 2013;9(1):39-55. [PUBMED: 23241154]
48. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. [: http://ims.cochrane.org/revman]
49. Schnell-Inderst P, Hunger T, Hintringer K, Schwarzer R, Seifert-Klauss VR, Gothe H, et al.Individual health services. GMS Health Technology Assessment 2011;7:1-15. [PUBMED: 21966301]
50. Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. American Journal of Pathology 2004;164(5):1511-8. [PUBMED: 15111296]
51. Slomski A. Screening women for ovarian cancer still does more harm than good. JAMA 2012;307(23):2474-5. [PUBMED: 22797429]
52. van Nagell JR, Miller RW, DeSimone CP, Ueland FR, Podzielinski I, Goodrich ST, et al.Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstetrics and Gynecology 2011;118(6):1212-21. [PUBMED: 22105249]
53. van Nagell JR, Pavlik EJ. Ovarian cancer screening. Clinical Obstetrics and Gynecology 2012;55(1):43-51. [PUBMED: 22343228]
54. Wegwarth O, Gigerenzer G. Less is more: Overdiagnosis and overtreatment: evaluation of what physicians tell their patients about screening harms. JAMA Internal Medicine 2013;173(22):2086-7. [PUBMED: 24145597]
55. Whitehouse C, Solomon E. Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening. Gynecologic Oncology 2003;88(1 Pt 2):S152-7. [PUBMED: 12586109]
56. Woolf SH, Harris R. The harms of screening: new attention to an old concern. JAMA 307;6:565-6. [PUBMED: 22318274]